Last updated 11 days ago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
332 patients around the world
Available in Argentina, Chile, United States
Seagen Inc.
8Research sites
332Patients around the world
This study is for people with
Urothelial cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Asociación de Beneficencia Hospital Sirio Libanes - CABA, Buenos Aires
Recruiting
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Centro de Oncología e Investigación Buenos Aires COIBA
Recruiting
Hospital Alemán
Recruiting
Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
Recruiting
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
StudyKEYNOTE-D78
SponsorSeagen Inc.
Study typeInterventional
Conditions
Urothelial cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04879329
